Longevity peptide stacks and combinations
An aggregated overview of the peptide combinations discussed across this site's protocol pages and comparison articles, gathered here in one place for readers researching combination approaches.
A "stack" in peptide-research terminology refers to two or more peptides administered concurrently on the premise that their distinct mechanisms will produce a combined effect greater than, or at least additive to, either compound used alone. The term is borrowed from bodybuilding and nootropic research-chemical communities, where combining compounds acting on different receptors or pathways is a long-standing practice, and it has migrated into longevity-peptide discussion for the same underlying reason: researchers reason from mechanism that pairing a signalling peptide with a structural peptide, or a repair-focused peptide with an immune-focused peptide, should in principle address more of the ageing phenotype than either alone.
The stacks summarised below are drawn directly from the protocol pages and comparison articles published on this site, gathered here so that a reader interested specifically in combination approaches does not have to piece them together from individual peptide and use-case pages. Each entry lists the peptides involved, the mechanistic rationale offered in the research literature for combining them, and — most importantly — an honest statement of how much of that rationale is actually supported by controlled evidence rather than by plausibility alone.
That honesty matters because the evidence bar for a combination is categorically higher than the evidence bar for either compound individually. A mechanistic case for non-overlapping pathways is not the same thing as a demonstrated combined effect, and as of this writing no stack discussed anywhere in the longevity-peptide research literature has been tested in a dedicated, controlled combination trial. Every stack below should be read as a research-context hypothesis assembled from separate single-agent evidence, not as a validated protocol.
Stacks by mechanism
GHRH + GHRP stack
A growth-hormone-releasing hormone (GHRH) analogue such as Sermorelin or CJC-1295 is paired with a ghrelin-receptor-agonist growth-hormone-releasing peptide (GHRP) such as Ipamorelin. The two act on distinct receptors upstream of pituitary somatotroph GH release, so the combination is proposed to produce a larger pulsatile GH release than either compound alone while preserving the feedback-regulated, pulsatile release pattern rather than flattening it into constant elevation.
Evidence caveat: The pairing is one of the more pharmacologically well-reasoned combinations in this field, but the long-term case for restoring youthful IGF-1 profiles as a longevity intervention in otherwise healthy older adults remains contested, and no dedicated combination RCT for longevity end-points has been published.
Mitochondrial stack
MOTS-c is a mitochondrial-derived signalling peptide that modulates AMPK activation and nuclear gene expression under metabolic stress, while SS-31 (elamipretide) is a structural cardiolipin-stabilising peptide that concentrates in the inner mitochondrial membrane. The two are proposed to act on orthogonal axes — signalling versus structural integrity — which gives a mechanistic rationale for combination even though the compounds were developed independently and for different original indications.
Evidence caveat: No clinical trial has tested the two compounds together. The theoretical non-overlap of mechanisms is the entire basis for the pairing; it has not been verified experimentally as additive or synergistic in vivo.
Telomere / pineal stack
Epitalon is studied for pineal-axis and telomerase-related effects, while GHK-Cu is the most-studied gene-regulatory and connective-tissue-repair peptide, with broad effects on extracellular-matrix gene expression. The rationale for pairing the two is that they address different hallmarks of ageing — telomere/pineal biology and tissue-repair capacity — rather than a shared molecular target.
Evidence caveat: This combination is widely discussed in research-peptide literature and forums but has no controlled-trial evidence base as a pairing. Each compound's individual evidence should be assessed separately before any inference is drawn about the combination.
Immune stack
Thymosin Alpha-1 is studied for restoration of T-cell-mediated immune function, addressing immunosenescence, while Epitalon is studied for telomere and pineal-axis effects, addressing replicative senescence. Immunosenescence and replicative senescence are both recognised hallmarks of ageing, so the pairing is framed as targeting two distinct ageing mechanisms concurrently rather than one mechanism from two angles.
Evidence caveat: The individual evidence bases for each compound differ substantially in depth and quality; combining them does not combine their evidence bases, and no published trial has tested the pair together for any immune or longevity end-point.
Recovery stack
BPC-157 is studied for angiogenic and growth-factor-receptor signalling relevant to tendon, ligament and gastric-mucosal repair, while TB-500 (Thymosin Beta-4) regulates actin dynamics underlying cell migration during wound healing. The combination is proposed on the basis that BPC-157 supplies vascular and growth-factor signalling while TB-500 supports the cell-migration component of the same repair process, making this the most frequently cited stack in the tissue-repair research literature.
Evidence caveat: No controlled clinical-trial data exists for the combination. Both compounds individually have a preclinical literature that substantially outweighs their human-trial evidence, and BPC-157 in particular has an unresolved translational gap despite a large rodent dataset.
Sleep / cognitive stack
Epitalon and Pinealon are both Khavinson-programme short peptides positioned within the same theoretical gene-regulatory framework, with Epitalon's evidence weighted towards pineal-axis and sleep-architecture outcomes and Pinealon's towards neurotropic and cognitive-measure outcomes. Delta-Sleep-Inducing Peptide (DSIP) is sometimes added to this stack in the research literature for its more direct slow-wave-sleep EEG signal, although DSIP does not have a dedicated peptide page on this site.
Evidence caveat: Co-administration is described in Russian-language gerontology literature as a generalised neuro-pineal-axis intervention, but this has not been tested against sleep-specific or cognitive end-points in a modern controlled design.
Important caveats
No controlled clinical trial of any peptide combination listed on this page has been published. Every rationale above is assembled from single-agent mechanistic and preclinical evidence, extrapolated to a combined context on the basis of plausibility rather than direct combination-trial data. This is a meaningful limitation: two compounds that each show a favourable effect in isolation do not necessarily produce a combined effect that is additive, let alone synergistic, when administered together, and it is equally possible for a combination to produce no measurable extra benefit or to introduce an interaction that neither single-agent study could have detected.
Additive and synergistic effects are frequently used interchangeably in informal peptide-research discussion, but they describe different things. An additive effect is one where the combined outcome equals the sum of each compound's individual effect; a synergistic effect is one where the combined outcome exceeds that sum. Establishing which (if either) applies to any stack on this page would require a factorial trial design comparing each compound alone against the combination — a study design that has not been carried out for any pairing discussed here.
Drug-interaction considerations also apply, even outside a formal clinical setting. Combining compounds that affect overlapping physiological systems (for example, two peptides that both influence growth-hormone axis signalling, or two peptides cleared through similar metabolic pathways) raises the theoretical possibility of compounding rather than independent effects, including on safety end-points that were only characterised for single-agent administration in the underlying research.
Under UK law, every peptide named on this page is a research chemical, not a licensed medicine. None of the compounds discussed is authorised by the MHRA for human therapeutic use under the Human Medicines Regulations 2012, whether administered alone or in combination, and nothing on this page should be read as a recommendation to combine research compounds for any human use.
Related reading
For the full use-case context behind several of the stacks above, see the protocol pages on peptides for cognitive decline, peptides for recovery and peptides for sleep. A narrower, side-by-side treatment of the most-discussed combinations is also available on Best longevity peptide stacks discussed in research, and the full set of use-case overviews is indexed on the Protocols page.